Response assessment criteria for brain metastases: proposal from the RANO group

被引：736

作者：

Lin, Nancy U. ^{[1
]}

Lee, Eudocia Q. ^{[2
]}

Aoyama, Hidefumi ^{[3
]}

Barani, Igor J. ^{[4
]}

Barboriak, Daniel P. ^{[5
]}

Baumert, Brigitta G. ^{[6
,7
]}

Bendszus, Martin ^{[8
]}

Brown, Paul D. ^{[9
]}

Camidge, D. Ross ^{[10
]}

Chang, Susan M. ^{[11
]}

Dancey, Janet ^{[12
]}

de Vries, Elisabeth G. E. ^{[13
]}

Gaspar, Laurie E. ^{[14
]}

Harris, Gordon J. ^{[15
]}

Hodi, F. Stephen ^{[1
]}

Kalkanis, Steven N. ^{[16
]}

Linskey, Mark E. ^{[17
,18
]}

Macdonald, David R. ^{[19
]}

Margolin, Kim ^{[20
]}

Mehta, Minesh P. ^{[21
]}

Schiff, David ^{[22
]}

Soffietti, Riccardo ^{[23
]}

Suh, John H. ^{[24
]}

van den Bent, Martin J. ^{[26
]}

Vogelbaum, Michael A. ^{[25
]}

Wen, Patrick Y. ^{[2
]}

机构：

[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, Ctr Neurooncol, Boston, MA 02215 USA

[3] Niigata Univ, Grad Sch Med & Dent Sci, Dept Radiol, Chuo Ku, Niigata, Japan

[4] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA

[5] Duke Univ, Med Ctr, Dept Radiol, Durham, NC 27710 USA

[6] MediClin Robert Janker Clin, Dept Radiat Oncol, Bonn, Germany

[7] Univ Bonn, Med Ctr, Cooperat Unit Neurooncol, Bonn, Germany

[8] Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany

[9] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA

[10] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA

[11] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA

[12] Queens Univ, Ontario Inst Canc Res, NCIC Clin Trials Grp, Kingston, ON, Canada

[13] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands

[14] Univ Colorado Denver, Dept Radiat Oncol, Aurora, CO USA

[15] Massachusetts Gen Hosp, MGH Imaging Lab 3D, Boston, MA 02114 USA

[16] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA

[17] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA

[18] UC Irvine Med Ctr, Orange, CA USA

[19] Univ Western Ontario, Dept Oncol, London Reg Canc Program, London Hlth Sci Ctr, London, ON, Canada

[20] Stanford Univ, Div Oncol, Stanford, CA 94305 USA

[21] Univ Maryland, Sch Med, Maryland Proton Treatment Ctr, Baltimore, MA USA

[22] Univ Virginia, Div Neurooncol, Charlottesville, VA USA

[23] Univ Turin, Dept Neurol Neurooncol, Turin, Italy

[24] Cleveland Clin, Rose Ella Burkhardt Brain Tumor & Neurooncol Ctr, Dept Radiat Oncol T28, Cleveland, OH 44106 USA

[25] Cleveland Clin, Rose Ella Burkhardt Brain Tumor & Neurooncol Ctr, Dept Neurosurg ND40, Cleveland, OH 44106 USA

[26] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Neurooncol Unit, Rotterdam, Netherlands

来源：

LANCET ONCOLOGY | 2015年 / 16卷 / 06期

关键词：

GAMMA-KNIFE RADIOSURGERY; VOLUMETRIC DATA ERRORS; SOLID TUMORS; CLINICAL-TRIALS; BREAST-CANCER; PHASE-II; GUIDELINES; MR;

D O I：

10.1016/S1470-2045(15)70057-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now becoming more common. The medical literature is difficult to interpret because of substantial variation in the response and progression criteria used across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases. Previous efforts have focused on aspects of trial design, such as patient population, variations in existing response and progression criteria, and challenges when incorporating neurological, neuro-cognitive, and quality-of-life endpoints into trials of patients with brain metastases. Here, we present our recommendations for standard response and progression criteria for the assessment of brain metastases in clinical trials. The proposed criteria will hopefully facilitate the development of novel approaches to this difficult problem by providing more uniformity in the assessment of CNS metastases across trials.

引用

页码：E270 / E278

页数：9

共 23 条

[1] [Anonymous], 2007, CANC FACTS FIG
[2] Intra- and Interobserver Variability of Linear and Volumetric Measurements of Brain Metastases Using Contrast-Enhanced Magnetic Resonance Imaging
Bauknecht, Hans-Christian
Romano, Valentina C.
Rogalla, Patrik
Klingebiel, Randolf
Wolf, Claudia
Bornemann, Lars
Hamm, Bernd
Hein, Patrick A.
[J]. INVESTIGATIVE RADIOLOGY, 2010, 45 (01) : 49 - 56
[3] Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data
Davis, Faith G.
Dolecek, Therese A.
McCarthy, Bridget J.
Villano, John L.
[J]. NEURO-ONCOLOGY, 2012, 14 (09) : 1171 - 1177
[4] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Eisenhauer, E. A.
Therasse, P.
Bogaerts, J.
Schwartz, L. H.
Sargent, D.
Ford, R.
Dancey, J.
Arbuck, S.
Gwyther, S.
Mooney, M.
Rubinstein, L.
Shankar, L.
Dodd, L.
Kaplan, R.
Lacombe, D.
Verweij, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
[5] Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II
Harris, Gordon J.
Plotkin, Scott R.
MacCollin, Mia
Bhat, Shubha
Urban, Trinity
Lev, Michael H.
Slattery, William H.
[J]. NEUROSURGERY, 2008, 62 (06) : 1314 - 1319
[6] Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Hudis, Clifford A.
Barlow, William E.
Costantino, Joseph P.
Gray, Robert J.
Pritchard, Kathleen I.
Chapman, Judith-Anne W.
Sparano, Joseph A.
Hunsberger, Sally
Enos, Rebecca A.
Gelber, Richard D.
Zujewski, Jo Anne
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) : 2127 - 2132
[7] Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group
Lin, Nancy U.
Lee, Eudocia Q.
Aoyama, Hidefumi
Barani, Igor J.
Baumert, Brigitta G.
Brown, Paul D.
Camidge, D. Ross
Chang, Susan M.
Dancey, Janet
Gaspar, Laurie E.
Harris, Gordon J.
Hodi, F. Stephen
Kalkanis, Steven N.
Lambom, Kathleen R.
Linskey, Mark E.
Macdonald, David R.
Margolin, Kim
Mehta, Minesh P.
Schiff, David
Soffietti, Riccardo
Suh, John H.
van den Bent, Martin J.
Vogelbaum, Michael A.
Wefel, Jeffrey S.
Wen, Patrick Y.
[J]. LANCET ONCOLOGY, 2013, 14 (10) : E396 - E406
[8] Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group
Lin, Nancy U.
Wefel, Jeff Rey S.
Lee, Eudocia Q.
Schiff, David
van den Bent, Martin J.
Soffietti, Riccardo
Suh, John H.
Vogelbaum, Michael A.
Mehta, Minesh P.
Dancey, Janet
Linskey, Mark E.
Camidge, D. Ross
Aoyama, Hidefumi
Brown, Paul D.
Chang, Susan M.
Kalkanis, Steven N.
Barani, Igor J.
Baumert, Brigitta G.
Gaspar, Laurie E.
Hodi, F. Stephen
Macdonald, David R.
Wen, Patrick Y.
[J]. LANCET ONCOLOGY, 2013, 14 (10) : E407 - E416
[9] Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Lin, Nancy U.
Dieras, Veronique
Paul, Devchand
Lossignol, Dominique
Christodoulou, Christos
Stemmler, Hans-Joachim
Roche, Henri
Liu, Minetta C.
Greil, Richard
Ciruelos, Eva
Loibl, Sibylle
Gori, Stefania
Wardley, Andrew
Yardley, Denise
Brufsky, Adam
Blum, Joanne L.
Rubin, Stephen D.
Dharan, Bernie
Steplewski, Klaudia
Zembryki, Denise
Oliva, Cristina
Roychowdhury, Debasish
Paoletti, Paolo
Winer, Eric P.
[J]. CLINICAL CANCER RESEARCH, 2009, 15 (04) : 1452 - 1459
[10] RESPONSE CRITERIA FOR PHASE-II STUDIES OF SUPRATENTORIAL MALIGNANT GLIOMA
MACDONALD, DR
CASCINO, TL
SCHOLD, SC
CAIRNCROSS, JG
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (07) : 1277 - 1280

← 1 2 3 →